Results 91 to 100 of about 5,939 (158)

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study

Journal of Dermatological Treatment
Purpose: Atopic dermatitis (AD) adversely impacts quality of life (QoL). We evaluated the effect of upadacitinib, an oral selective Janus kinase inhibitor approved for moderate-to-severe AD, plus topical corticosteroids (+TCS) on patient-reported ...
Nina Magnolo, Michael C. Cameron, Mona Shahriari, Bob Geng, Brian M. Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Yingyi Liu, Shiyu Zhang, Cristina Sancho Sanchez, Katherine Altman, Richard G. Langley   +12 more
doaj   +1 more source

Systematic analysis of adverse reaction signals induced by leflunomide, upadacitinib, and baricitinib in the treatment of rheumatoid arthritis: a FAERS database analysis

Frontiers in Medicine
PurposeRheumatoid arthritis (RA) is a widely recognized chronic inflammatory disease. Leflunomide, upadacitinib, and baricitinib are frequently used to treat inflammatory diseases, including RA, although understanding of their associated adverse drug ...
Jizheng Dang, Li Shu
doaj   +1 more source

Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis

Clinical and Translational Science
Upadacitinib is an orally administered, selective, Janus kinase inhibitor that is approved for several auto‐immune conditions, such as axial spondyloarthritis, an inflammatory rheumatic disease that includes ankylosing spondylitis (AS) and non ...
Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In‐Ho Song, Peter Wung, Wei Liu, Mohamed‐Eslam F. Mohamed   +6 more
doaj   +1 more source

A Successful Outcome of Upadacitinib Therapy in a Patient with Genital Erosive Fixed Drug Eruption: A Case Report. [PDF]

Clin Cosmet Investig Dermatol
Li C, Wang X, Li X, Xu M, Kong S, Tao X, Liu W, Wan H.   +7 more
europepmc   +1 more source

The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia. [PDF]

Clinicoecon Outcomes Res
Abu-Shraie N, Al-Sheikh A, Alharbi I, Alanizy L, Alshraim M, Khoshhal SI, AlSalman SA, Alrumaih A, Fasseeh AN, Elezbawy B, Abaza N, Semida A, George M, Amin S, Binamer Y.   +14 more
europepmc   +1 more source

Dual Targeted Therapy With Risankizumab and Upadacitinib in Refractory Ulcerative Colitis. [PDF]

ACG Case Rep J
Srivoleti P, Dhillon N, Boneschansker L.
europepmc   +1 more source

Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn's Disease: A Three-Patient Case Series. [PDF]

Inflamm Bowel Dis
Hanna LN, Quraishi B, Pelly T, Lung P, Tozer P, Hart A, Wong SY, Powell N.   +7 more
europepmc   +1 more source

Efficacy and safety of upadacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. [PDF]

Front Immunol
Xu YH, Liu D, Zhang MR, Zhang YJ, Li M, Yang QR.   +5 more
europepmc   +1 more source

Upadacitinib for Severe Refractory Hidradenitis Suppurativa After Failure of Multiple Systemic Therapies: A Case Report. [PDF]

Cureus
Chew Bonilla E, Vega-Del Pilar X, Benitez Rocha S, Miranda Contreras N, Lemini López A.   +4 more
europepmc   +1 more source

Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review. [PDF]

Front Immunol
Wang T, Zhang X, Wang J, Zhuang K, Wang T.   +4 more
europepmc   +1 more source